Featured
News
Spotlight on the generics industry: New analysis looks at access efforts of 5 major companies
26 September 2023
Foundation investor event: 2023 company profiles from Generic and Biosimilar Medicines Programme report
Following the September launch of the first report from its Generic and Biosimilar Medicines Programme, the Access to Medicine Foundation will host an investor-focused event in London in partnership with Nomura. The company profiles of the five market-leading generic and biosimilar producers assessed in the report will be central to the event, which will include a panel discussion on advancing access to medicine through investment stewardship.
Date
19 October 2023
Date:
Mid-October
Location:
London, UK
Participation:
Invitation only
The Access to Medicine Foundation’s newly established Generic and Biosimilar Medicine Manufacturers Programme released its inaugural research report on 26 September 2023. This report is the Foundation’s first independent assessment of generic medicine and biosimilar medicine manufacturers’ actions on expanding access to medicine, and includes profiles of five leading companies: Cipla, Hikma, Sun Pharma, Teva, and Viatris. Company performance was assessed using a first-of-its-kind analytical framework developed under the Programme.  Â
As part of the launch of the report, the Foundation is co-hosting an investor-focused event with Nomura in mid-October. Investors and global health stakeholders will have the opportunity to delve into the report's findings and discuss how companies and other sector partners can collaborate effectively to expand access to essential generic and biosimilar medicines in low-and middle-income countries. Â
Event agendaÂ
As co-hosts, the Access to Medicine Foundation and Nomura will jointly welcome participants and open the event, which will include a presentation of the report, a Q&A session and a moderated panel discussion.Â
Presentation: From insight to impact – assessing access efforts via the 2023 company profiles – Claudia Martinez, Research Programme Manager, Access to Medicine Foundation & Suzi van Es, Investor Engagement Manager, Access to Medicine FoundationÂ
Q&A session: Opportunity for attendees to pose questions to the programme’s Research Manager and the Investor Engagement team. Â
Moderated panel discussion: Fostering engagement in generic and biosimilar medicines Â
Moderator: Suzi van Es, Investor Engagement Manager, Access to Medicine FoundationÂ
Panelists:Â
Ellen Brauers, ESG Analyst, Columbia Threadneedle Investments
Benjamin Lacaille, Equity Analyst, Nomura Asset Management
Daniel Ryan, Associate Analyst, T. Rowe PriceÂ
Rogier Snijdewind, Director Active Ownership, PGGM
Clare Wood, Portfolio Specialist, Stewart InvestorsÂ
